4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus ErythematosusSkin and Connective Tissue Diseases, autoimmune disease, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, subacute cutaneous lupus erythematosus, systemic lupus erythematosusActive, not recruitingPhase 2 / Phase 32026-10-09NCT05531565
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorderRecruitingPhase 32026-09-30NCT06935357
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Primary Membranous NephropathyRecruitingPhase 32026-09-29NCT06962800
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)Arterial Occlusive Diseases, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infarction, Male Urogenital Diseases, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, ischemic disease, kidney disorder, kidney failure, metabolic disease, myocardial infarction, myocardial ischemia, peripheral arterial disease, peripheral vascular disease, urinary system disorder, vascular disorderRecruitingPhase 2 / Phase 32026-09-21NCT05485961